Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (Kelun-Biotech) is a China-based biopharmaceutical company focused on the discovery, development, and manufacturing of biologic therapies. Headquartered in Chengdu, Sichuan, it is affiliated with Sichuan Kelun Pharmaceutical Co., Ltd. and concentrates on treatments for oncology and immune-related diseases.
The company’s R&D capabilities span monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates (ADCs), advancing candidates from early discovery into clinical studies. Kelun-Biotech operates GMP-compliant facilities for process development and clinical-scale manufacturing of biologic drug substance and drug product. It also engages in collaborations and licensing with domestic and international partners, with programs that include TROP2-targeting and other ADC candidates under clinical evaluation.
Also known as Kelun Pharmaceutical Co, Ltd..
None yet. When a new project in the record names Kelun-Biotech as owner, partner or investor, it shows here.
TroFuse‑005 (776 pts) showed significant OS and PFS improvement vs chemotherapy in advanced/recurrent endometrial cancer after platinum and anti‑PD‑1/PD‑L1 therapy; ORR met; safety consistent.
New data shows improved survival rates for bladder and kidney cancer treatments, highlighting advancements in Merck's oncology portfolio at the ASCO GU Symposium.
Merck receives $700M from Blackstone for sac-TMT development, retaining control over its progress and commercialization.
